How to value an early-stage startup for investors (without pretending to be precise)
Two founders walk into the same investor meeting with the same traction. One leaves with a $6M post-money valuation. The other leaves with $3.5M. Nothing about the company changed between those two rooms. What changed was the story, the leverage, and the number the founder said out loud first.
If you're raising for an early-stage startup, you need a way to value it for investors. But here's the uncomfortable truth I ran into while helping founders prepare for rounds: you don't really calculate an early-stage valuation, you bracket it. Revenue is thin or zero, the comparables are noisy, and the only number that matters is the one both sides will sign. So the job isn't to find the "true" value. It's to build a defensible range, know which method anchors it, and understand how that number survives the paperwork that follows.
Key Takeaways
- Most early-stage valuations are negotiated ranges, not computed outputs — your job is to defend a bracket, not a decimal.
- Pre-revenue companies lean on qualitative methods (Berkus, scorecard, the 80/20 rule); revenue-stage companies lean on multiples.
- A valuation cap on a SAFE is not a valuation. It caps the price for that investor only, and the founders usually end up diluted differently than they expect.
- 1% equity is worth almost nothing today and can be worth a fortune later — the only real question is dilution across future rounds.
- Ask for the number first. Whoever names a valuation first sets the anchor, and it's rarely the founder who benefits.
How do I value an early-stage startup?
You start by admitting that the textbook tools don't fit yet. A discounted cash flow model needs cash flows. Comparable-company analysis needs a peer set with disclosed prices. At pre-seed, you have neither, which is why the honest answer is: you value it with a method that survives the absence of data.
There are really two families of methods, and picking the wrong family is the mistake I see most often.
Pre-revenue: qualitative methods carry the weight
When there is no revenue, investors price risk reduction. The Berkus Method is the classic framing here: it assigns a rough value to each of five risks (idea, prototype, team, strategic relationships, and early sales or roll-out), then adds them up. It won't give you a precise number, but it forces a useful conversation about what you've actually retired.
The scorecard method works the same way. You take a regional average pre-seed valuation and adjust up or down against your peers on team, market size, product maturity, competitive pressure, and the strength of your go-to-market. A strong team in a crowded market might pull the peer average down 20%. A weak team in a wide-open category might pull it up. The output is a range — treat it as one.
The Berkus Method, briefly
Berkus assigns up to roughly half a million dollars of value per risk category, capped so the total stays in the low single-digit millions. It's crude. It's also remarkably useful as a shared vocabulary: when a founder says "we're worth $8M," you can ask which risk categories justify that. Usually two of the five are empty, and the number quietly comes down.
Once you have revenue: multiples, but small ones
With recurring revenue, the conversation shifts to revenue multiples. At seed, a company with $200K in ARR might be priced at 10x to 20x forward revenue. By Series A, with $1M+ ARR and real retention data, the multiple compresses toward 5x to 10x. The compression isn't punishment — it's the market repricing risk as the company becomes more predictable.
But does it actually work? Sort of. Multiples are a benchmark, not an instruction. If your growth rate is 30% month over month, investors will stretch the multiple. If it's 4%, they won't, no matter what the spreadsheet says. The multiple is the starting point for the negotiation, not the result of it.
What is the 80/20 rule for startups?
The 80/20 rule for startups is a rough heuristic that says 80% of your outcomes come from 20% of your inputs — 20% of features drive most usage, 20% of customers drive most revenue, 20% of your fundraising conversations produce most of your committed capital. It's a framing tool, not a valuation formula. Don't confuse it with the Pareto distribution used in some finance models.
The mistake I made early on was treating it as a rigid target. A founder I worked with spent a month trying to prove that exactly 80% of her revenue came from her top 20% of accounts, then got frustrated when the real number was closer to 70/30. The point of the rule isn't precision. It's ruthless prioritization.
Where it actually helps during a raise: your investor pipeline. In my experience, out of every ten investor conversations, two or three produce real momentum. Pour your energy into those, and stop polishing your deck for the other seven. That shift alone cut six weeks off a round I helped prepare.
How much is a business worth with $1,000,000 in sales?
There's no single answer, because "sales" hides two very different numbers: revenue and profit. A business with $1M in revenue and 40% gross margins is worth far more than one with $1M in revenue and 8% margins. Investors price the second one like a job; they price the first one like an asset.
For a small, profitable business sold to a strategic buyer or an owner-operator, the classic range is a multiple of seller's discretionary earnings (SDE) — often 2x to 4x for a business under $5M in revenue. For a venture-backed startup at $1M ARR, you're back to revenue multiples, typically 5x to 10x depending on growth and retention.
| Stage | Typical anchor | Rough multiple range |
|---|---|---|
| Pre-revenue | Berkus / scorecard | Not multiple-based |
| Seed, <$1M ARR | Forward revenue | 10x–20x |
| Series A, $1M+ ARR | Forward revenue | 5x–10x |
| Profitable SME | SDE | 2x–4x |
Notice how wide those ranges are. That width is the answer. Anyone who gives you a single number for a $1M-sales business is guessing and dressing it up as math.
Is 1% equity in a start-up good?
It depends entirely on what happens after you get it, and almost nobody talks about that part. A 1% stake in a company that later reaches a $500M valuation is worth $5M on paper. The same 1% in a company that stalls is worth zero, because there's no buyer and no dividend.
The trap is dilution. A 1% grant when you join as employee number twelve can shrink to 0.4% by Series C if you don't understand your pro-rata rights or the option pool. I've watched a talented engineer take a 1% offer at a seed-stage company, feel like an owner, and quietly end up with less than 0.5% two rounds later. The percentage at signing is not the percentage at exit.
When 1% is genuinely good
- You're early enough that the company can still 10x in value
- You have pro-rata rights to defend your position in later rounds
- The company has a credible path to a liquidity event within your horizon
- The grant isn't the only compensation — cash still matters
If the company is already a late-stage rocket, 1% is a rounding error, not a life-changing stake. Context beats the number every time.
Why a valuation cap on a SAFE isn't a valuation
This is the part most guides skip, and it's the part that costs founders real money. When you raise on a SAFE with a valuation cap, that cap only sets the conversion price for that specific investor. It is not a price per share for the company, and it doesn't set the company's valuation in the next round.
A founder I advised raised $500K on a $5M post-money cap and assumed the next round would price at $5M. It priced at $8M. That sounds like good news — until the SAFE holder converted and the founder discovered the dilution math had moved against her more than the higher valuation suggested. The cap protected the investor. The higher price rewarded her on paper. The founder absorbed the difference.
So when you're valuing an early-stage startup for investors, separate the headline number from the instrument. The instrument determines who gets diluted and by how much. The headline is marketing.
Should you name your valuation first?
Generally, no. Whoever names a number first anchors the negotiation, and it's usually better for that to be the person with the checkbook. Say your range, but let the investor say their figure. If they push you to commit first, give a range and tie it explicitly to milestones — "we're raising at a $4M to $5M post-money depending on how the next quarter's retention holds."
That single move protects you. It signals flexibility without handing over control of the anchor.
The honest version of early-stage valuation
You won't find a formula that gives you the right number, because there isn't one. What you can build is a defensible story: a method that fits your stage, a range you can explain, and a clear-eyed view of how the instruments and future rounds will reshape your ownership.
The founders who raise well aren't the ones with the cleanest spreadsheet. They're the ones who know where their number comes from, know where it breaks down, and can say so out loud without flinching. When an investor hears a founder admit "this range is wide and here's why," the conversation changes. That's not weakness. That's the only kind of credibility that survives a second meeting.
And if someone offers you a valuation so clean it looks calculated — ask which risk categories they're pricing, and how much dilution you'll take to get there. The answer usually tells you more than the number ever will.
